Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Michael Dickinson et al.|Nature Medicine|2021Cited by 523
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant ResearchSally Arai, Yoshiko Atsuta, Minoo Battiwalla et al.|Biology of Blood and Marrow Transplantation|2014Cited by 435
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey studyJosè Antonio Pérez-Simón, Virginia Escamilla Gómez, Valentín García‐Gutiérrez et al.|Bone Marrow Transplantation|2019Cited by 90
Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)Marta Peña, Alberto Mussetti, Giulia Losi et al.|Blood|2024Cited by 2
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)Catherine Thiéblemont, Nathan Fowler, M. Dreyling et al.|Hematological Oncology|2025Cited by 1